A Study Assessing the Use of Serial FLT PET/CT Imaging to Monitor Response to Therapy in People with Cancer

Protocol
14-050
Full Title
Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy
Disease Status
Relapsed/Refractory
Purpose

Radioactive substances called radiotracers are used in positron emission tomography (PET)/computed tomography (CT) scanning to visualize cancer cell activity (metabolism). Standard PET/CT scanning uses radiolabelled fluorodeoxyglucose (FDG). In this study, researchers are evaluating a new type of PET/CT scanning that uses radiolabelled fluorothymidine (FLT).

The investigators are assessing FLT PET/CT scanning to see if it is useful for monitoring how patients’ tumors are responding to anticancer agents being evaluated in certain other clinical trials at Memorial Sloan Kettering. The amount of radiation that patients receive is small and is eliminated from the body in a few hours.

Eligibility

This study will include patients age 18 and older who are being treated for cancer through another clinical trial at Memorial Sloan Kettering.

For more information about this study, please contact Dr. Heiko Schoder at 212-639-8001.

Disease(s)
Solid Tumors
Locations